Vimarsana
Biggest News Aggregation in the World

Page 5 - Events Presentations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Events Presentations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Events Presentations Today - Breaking & Trending Today

EVgo to Host European Investor Meetings - Vimarsana News

EVgo to Host European Investor Meetings

EVgo Inc. (Nasdaq: EVGO, or the "Company"), a first mover in fleet electrification and owner and operator of first electric vehicle (EV) network powered by 100% renewable electricity, today announced

ADC Therapeutics SA: ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference - Vimarsana News

ADC Therapeutics SA: ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients

ADC Therapeutics SA: ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline - Vimarsana News

ADC Therapeutics SA: ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

Company to host webcast today at 9:00 a.m. EST ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation,

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease - Vimarsana News

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease

Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above

ADC Therapeutics SA: ADC Therapeutics to Participate in Guggenheim Oncology Conference - Vimarsana News

ADC Therapeutics SA: ADC Therapeutics to Participate in Guggenheim Oncology Conference

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients